Scott Eggener to Chemotherapy, Adjuvant
This is a "connection" page, showing publications Scott Eggener has written about Chemotherapy, Adjuvant.
Connection Strength
1.361
-
National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urol Oncol. 2020 08; 38(8):687.e13-687.e18.
Score: 0.566
-
Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98.
Score: 0.404
-
Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Curr Opin Urol. 2018 09; 28(5):461-468.
Score: 0.126
-
Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. Cancer. 2017 01 01; 123(2):245-252.
Score: 0.110
-
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour. BJU Int. 2025 Apr; 135(4):621-628.
Score: 0.049
-
Granulocytic sarcoma of the testis. Urology. 2004 Mar; 63(3):584-5.
Score: 0.046
-
A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database. Urol Oncol. 2023 01; 41(1):52.e11-52.e20.
Score: 0.042
-
The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Jun; 75(6):1431-5.
Score: 0.018